ciprofloxacin has been researched along with Critical Illness in 33 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Critical Illness: A disease or state in which death is possible or imminent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors determined the pharmacokinetic parameters of a new immediate-release ciprofloxacin suspension in tube-fed intensive care patients with bacterial pneumonia, to compare two dosage regimens: 500 mg b." | 9.10 | Pharmacokinetic parameters of ciprofloxacin (500 mg/5 mL) oral suspension in critically ill patients with severe bacterial pneumonia: a comparison of two dosages. ( Allaouchiche, B; Boselli, E; Breilh, D; Chassard, D; Debon, R; Duflo, F; Saux, MC, 2002) |
| "A critically ill patient with septicemic plague and peripheral gangrene was treated successfully with ciprofloxacin." | 7.72 | A case of plague successfully treated with ciprofloxacin and sympathetic blockade for treatment of gangrene. ( Kuberski, T; Robinson, L; Schurgin, A, 2003) |
| "Eighteen children with bacteriologically confirmed severe typhoid fever were initially treated intravenously with ciprofloxacin (10 mg/kg of body weight per day)." | 7.68 | Ciprofloxacin for treatment of severe typhoid fever in children. ( Bhattacharya, MK; Bhattacharya, SK; Dutta, P; Lahiri, M; Mitra, U; Rasaily, R; Saha, MR, 1993) |
| "In this two-centre randomised clinical trial, critically ill patients with sepsis or septic shock were randomised to AutoKinetics dosing or standard dosing for four antibiotics: vancomycin, ciprofloxacin, meropenem, and ceftriaxone." | 5.51 | Right dose, right now: bedside, real-time, data-driven, and personalised antibiotic dosing in critically ill patients with sepsis or septic shock-a two-centre randomised clinical trial. ( Bosman, RJ; de Grooth, HJ; Driessen, R; Elbers, PWG; Fleuren, LM; Girbes, ARJ; Guo, T; Mathot, RAA; Roggeveen, LF; Swart, EL; Thoral, P; van den Bogaard, B; van Hest, RM, 2022) |
| "To determine an adequate dosage of ciprofloxacin in critically ill medical patients on continuous venovenous haemofiltration, we studied the pharmacokinetics of ciprofloxacin in eight critically ill medical patients with renal failure treated with continuous venovenous haemofiltration using polysulfone membranes." | 5.31 | Pharmacokinetics of ciprofloxacin in patients with acute renal failure undergoing continuous venovenous haemofiltration: influence of concomitant liver cirrhosis. ( Bellmann, R; Bellmann-Weiler, R; Dunzendorfer, S; Egger, P; Gritsch, W; Joannidis, M; Wiedermann, ChJ, 2002) |
| "The authors determined the pharmacokinetic parameters of a new immediate-release ciprofloxacin suspension in tube-fed intensive care patients with bacterial pneumonia, to compare two dosage regimens: 500 mg b." | 5.10 | Pharmacokinetic parameters of ciprofloxacin (500 mg/5 mL) oral suspension in critically ill patients with severe bacterial pneumonia: a comparison of two dosages. ( Allaouchiche, B; Boselli, E; Breilh, D; Chassard, D; Debon, R; Duflo, F; Saux, MC, 2002) |
| "Twenty-four critically ill adult patients with acute kidney injury receiving ciprofloxacin, meropenem, piperacillin/tazobactam, or vancomycin during continuous renal replacement therapy." | 3.78 | Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. ( Bellomo, R; Cole, L; Lipman, J; Liu, X; Nair, P; Roberts, DM; Roberts, JA; Roberts, MS, 2012) |
| "To describe the pharmacokinetic profile and clinical outcome associated with high-dose ciprofloxacin therapy in a patient with the triad of extreme obesity, multiple organ failure, and deep-seated infection." | 3.76 | High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration. ( Callcut, RA; Healy, DP; Hurford, WE; Mueller, EW; Peterson, JD; Utrup, TR, 2010) |
| "A critically ill patient with septicemic plague and peripheral gangrene was treated successfully with ciprofloxacin." | 3.72 | A case of plague successfully treated with ciprofloxacin and sympathetic blockade for treatment of gangrene. ( Kuberski, T; Robinson, L; Schurgin, A, 2003) |
| "To determine the pharmacokinetic properties of ciprofloxacin in the critically ill, we studied seven mechanically ventilated patients with pneumonia during enteral feedings." | 3.69 | Enteric absorption of ciprofloxacin during tube feeding in the critically ill. ( Burns, GA; Cohn, SM; Milner, KA; Sawyer, MD; Tolomeo, C, 1996) |
| "Eighteen children with bacteriologically confirmed severe typhoid fever were initially treated intravenously with ciprofloxacin (10 mg/kg of body weight per day)." | 3.68 | Ciprofloxacin for treatment of severe typhoid fever in children. ( Bhattacharya, MK; Bhattacharya, SK; Dutta, P; Lahiri, M; Mitra, U; Rasaily, R; Saha, MR, 1993) |
| "In total, 388 (MIPD n = 189; standard dosing n = 199) patients were analysed (median age 64 [IQR 55-71])." | 3.11 | Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial. ( Abdulla, A; de Winter, BCM; Draisma, A; Endeman, H; Ewoldt, TMJ; Gommers, D; Haringman, J; Hunfeld, NGM; Karakus, A; Koch, BCP; Muller, AE; Purmer, IM; Rietdijk, WJR; Rijpstra, TA; van Vliet, P; Wils, EJ, 2022) |
| " Blood and ultrafiltrate samples were collected and assayed for ciprofloxacin by High Performance Liquid Chromatography (HPLC) to calculate the model independent pharmacokinetic parameters; total body clearance (TBC), half-life (t1/2) and volume of distribution (Vd)." | 2.76 | An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration. ( Corrigan, OI; D'Arcy, DM; Deegan, C; Donnelly, MB; Gowing, CM; Spooner, AM, 2011) |
| " enteral dosing was equivalent to that after 400 mg b." | 2.69 | Bioavailability of ciprofloxacin after multiple enteral and intravenous doses in ICU patients with severe gram-negative intra-abdominal infections. ( Bruining, HA; Buijk, SL; de Marie, S; Kluytmans, JA; Mouton, JW; van Vliet, A; VandenBergh, MF, 1998) |
| " These findings, when combined with pharmacokinetic data reported in the companion article, provide the rationale and tools needed for targeting the dosage of intravenous ciprofloxacin to individual patients' pharmacokinetics and their bacterial pathogens' susceptibilities." | 2.67 | Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. ( Ballow, CH; Birmingham, MC; Forrest, A; Goss, TF; Nix, DE; Schentag, JJ, 1993) |
| "Our study reports that established dosing recommendations for critically ill patients not on ECMO provides sufficient drug exposure for maximal ciprofloxacin activity for ECMO patients." | 1.72 | Population pharmacokinetics of ciprofloxacin in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study). ( Abdul-Aziz, MH; Burrows, F; Buscher, H; Cheng, V; Corley, A; Diehl, A; Fraser, JF; Levkovich, BJ; Pellegrino, V; Reynolds, C; Roberts, JA; Rudham, S; Shekar, K; Wallis, SC; Welch, SA, 2022) |
| " The usual dosing is 400 mg after 8-12 hours intravenously for one hour." | 1.62 | [Ciprofloxacin: pharmacokinetics and a potential for therapeutic monitoring]. ( Kubíčková, V; Urbánek, K, 2021) |
| " Subsequently, the pharmacokinetic profiles expected in patients with ARC receiving dosage regimens, including at the highest approved daily doses (meropenem 6 g daily divided and administered as 0." | 1.62 | Evaluation of Meropenem-Ciprofloxacin Combination Dosage Regimens for the Pharmacokinetics of Critically Ill Patients With Augmented Renal Clearance. ( Agyeman, AA; Bergen, PJ; Bulitta, JB; Kirkpatrick, CM; Landersdorfer, CB; Lipman, J; Nation, RL; Paterson, DL; Roberts, JA; Rogers, KE; Tait, JR; Wallis, SC, 2021) |
| "The objective of the present study was to develop a dosing algorithm for ciprofloxacin based on both renal function and pathogen susceptibility in critically ill patients." | 1.56 | Higher Dosage of Ciprofloxacin Necessary in Critically Ill Patients: A New Dosing Algorithm Based on Renal Function and Pathogen Susceptibility. ( Brüggemann, RJM; Burger, DM; de Lange, DW; Frenzel, T; Gieling, EM; Kolwijck, E; Pickkers, P; Schouten, JA; Ten Oever, J; Ter Heine, R; Wallenburg, E, 2020) |
| " Based on patient weight, higher ciprofloxacin dosing regimens should be used in critically ill patients when difficult-to-treat pathogens are suspected." | 1.43 | Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients. ( Lefrant, JY; Lipman, J; Louart, B; Muller, L; Roberts, JA; Roger, C; Wallis, SC, 2016) |
| " The main pharmacokinetic parameters for ciprofloxacin in the analyzed patients were as follows: k(el), 0." | 1.38 | Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg. ( Grabowski, T; Grześkowiak, E; Kaczmarek, Z; Kamińska, A; Matysiak, K; Smuszkiewicz, P; Szałek, E; Tomczak, H; Wolc, A, 2012) |
| "A population pharmacokinetic model was first developed on ciprofloxacin serum concentrations obtained in 102 ICU patients." | 1.37 | Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations. ( Conil, JM; Georges, B; Houin, G; Khachman, D; Laffont, CM; Saivin, S; Toutain, PL, 2011) |
| "We evaluated the pharmacokinetic profile of ciprofloxacin and its penetration into bronchial secretions of critically ill patients with chronic obstructive pulmonary disease (COPD)." | 1.37 | Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease. ( Argyropoulou-Pataka, P; Chatzika, K; Kioumis, I; Kontou, P; Pitsiou, G; Stanopoulos, I, 2011) |
| "Optimal dosing of antibiotics is important for efficacy and avoidance of resistance." | 1.35 | Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. ( Girbes, AR; Polderman, KH; Schouten, MA; van der Meer, GY; van Geijlswijk, IM; van Zanten, AR, 2008) |
| "Ciprofloxacin clearance was 13." | 1.35 | Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches. ( Conil, JM; Cougot, P; de Lussy, A; Fourcade, O; Georges, B; Houin, G; Khachman, D; Ruiz, S; Saivin, S; Seguin, T, 2008) |
| "Lowering ciprofloxacin dosage in the presence of renal failure seems in most cases unnecessary, since drug accumulation occurred only in a few cases." | 1.33 | Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective. ( Furlanut, M; Pavan, F; Pea, F; Poz, D; Viale, P, 2006) |
| "To determine an adequate dosage of ciprofloxacin in critically ill medical patients on continuous venovenous haemofiltration, we studied the pharmacokinetics of ciprofloxacin in eight critically ill medical patients with renal failure treated with continuous venovenous haemofiltration using polysulfone membranes." | 1.31 | Pharmacokinetics of ciprofloxacin in patients with acute renal failure undergoing continuous venovenous haemofiltration: influence of concomitant liver cirrhosis. ( Bellmann, R; Bellmann-Weiler, R; Dunzendorfer, S; Egger, P; Gritsch, W; Joannidis, M; Wiedermann, ChJ, 2002) |
| "Levofloxacin clearance was substantially increased during both CVVH and CVVHDF, while ciprofloxacin clearance was affected less." | 1.31 | Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients. ( Abraham, E; Fish, DN; Malone, RS; Teitelbaum, I, 2001) |
| " Ciprofloxacin bioavailability ranges from 31 to 82 % (median, 44%)." | 1.30 | Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients. ( Binter, V; Edouard, A; Jacolot, A; Mimoz, O; Petitjean, O; Samii, K; Tod, M, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (15.15) | 18.2507 |
| 2000's | 8 (24.24) | 29.6817 |
| 2010's | 13 (39.39) | 24.3611 |
| 2020's | 7 (21.21) | 2.80 |
| Authors | Studies |
|---|---|
| Peña, C | 1 |
| Guzmán, A | 1 |
| Suarez, C | 1 |
| Dominguez, MA | 1 |
| Tubau, F | 1 |
| Pujol, M | 1 |
| Gudiol, F | 1 |
| Ariza, J | 1 |
| Berger, FA | 1 |
| van Weteringen, W | 1 |
| van der Sijs, H | 1 |
| Hunfeld, NGM | 2 |
| Bunge, JJH | 1 |
| de Groot, NMS | 1 |
| van den Bemt, PMLA | 1 |
| van Gelder, T | 1 |
| Urbánek, K | 1 |
| Kubíčková, V | 1 |
| Cheng, V | 1 |
| Abdul-Aziz, MH | 1 |
| Burrows, F | 1 |
| Buscher, H | 1 |
| Corley, A | 1 |
| Diehl, A | 1 |
| Levkovich, BJ | 1 |
| Pellegrino, V | 1 |
| Reynolds, C | 1 |
| Rudham, S | 1 |
| Wallis, SC | 4 |
| Welch, SA | 1 |
| Roberts, JA | 5 |
| Shekar, K | 2 |
| Fraser, JF | 2 |
| Roggeveen, LF | 1 |
| Guo, T | 1 |
| Fleuren, LM | 1 |
| Driessen, R | 1 |
| Thoral, P | 1 |
| van Hest, RM | 1 |
| Mathot, RAA | 1 |
| Swart, EL | 1 |
| de Grooth, HJ | 1 |
| van den Bogaard, B | 1 |
| Girbes, ARJ | 1 |
| Bosman, RJ | 1 |
| Elbers, PWG | 1 |
| Ewoldt, TMJ | 1 |
| Abdulla, A | 1 |
| Rietdijk, WJR | 1 |
| Muller, AE | 1 |
| de Winter, BCM | 1 |
| Purmer, IM | 1 |
| van Vliet, P | 1 |
| Wils, EJ | 1 |
| Haringman, J | 1 |
| Draisma, A | 1 |
| Rijpstra, TA | 1 |
| Karakus, A | 1 |
| Gommers, D | 1 |
| Endeman, H | 1 |
| Koch, BCP | 1 |
| Gieling, EM | 1 |
| Wallenburg, E | 1 |
| Frenzel, T | 1 |
| de Lange, DW | 1 |
| Schouten, JA | 1 |
| Ten Oever, J | 1 |
| Kolwijck, E | 1 |
| Burger, DM | 1 |
| Pickkers, P | 1 |
| Ter Heine, R | 1 |
| Brüggemann, RJM | 1 |
| Agyeman, AA | 1 |
| Rogers, KE | 1 |
| Tait, JR | 1 |
| Bergen, PJ | 1 |
| Kirkpatrick, CM | 1 |
| Bulitta, JB | 1 |
| Paterson, DL | 1 |
| Lipman, J | 3 |
| Nation, RL | 1 |
| Landersdorfer, CB | 1 |
| Li, X | 1 |
| Zoller, M | 1 |
| Fuhr, U | 1 |
| Huseyn-Zada, M | 1 |
| Maier, B | 1 |
| Vogeser, M | 1 |
| Zander, J | 1 |
| Taubert, M | 1 |
| Tokatly Latzer, I | 1 |
| Nahum, E | 1 |
| Cavari, Y | 1 |
| Lazar, I | 1 |
| Ben-Ari, Y | 1 |
| Ben-Shimol, S | 1 |
| Ben-Shalom, G | 1 |
| Geffen, Y | 1 |
| Goldberg, L | 1 |
| Rubinstein, M | 1 |
| Keller, N | 1 |
| Pessach, IM | 1 |
| Paret, G | 1 |
| Jensen, JU | 1 |
| Hein, L | 1 |
| Lundgren, B | 1 |
| Bestle, MH | 1 |
| Mohr, T | 1 |
| Andersen, MH | 1 |
| Løken, J | 1 |
| Tousi, H | 1 |
| Søe-Jensen, P | 1 |
| Lauritsen, AØ | 1 |
| Strange, D | 1 |
| Petersen, JA | 1 |
| Thormar, K | 1 |
| Larsen, KM | 1 |
| Drenck, NE | 1 |
| Helweg-Larsen, J | 1 |
| Johansen, ME | 1 |
| Reinholdt, K | 1 |
| Møller, JK | 1 |
| Olesen, B | 1 |
| Arendrup, MC | 1 |
| Østergaard, C | 1 |
| Cozzi-Lepri, A | 1 |
| Grarup, J | 1 |
| Lundgren, JD | 1 |
| Shotwell, MS | 1 |
| Madonia, PN | 1 |
| Connor, MJ | 1 |
| Amde, M | 1 |
| Salem, C | 1 |
| Aduroja, OA | 1 |
| Bauer, SR | 1 |
| Groszek, JJ | 1 |
| Fissell, WH | 1 |
| Barnett, AG | 1 |
| Diab, S | 1 |
| Fung, YL | 1 |
| Roger, C | 1 |
| Louart, B | 1 |
| Lefrant, JY | 1 |
| Muller, L | 1 |
| van Zanten, AR | 1 |
| Polderman, KH | 1 |
| van Geijlswijk, IM | 1 |
| van der Meer, GY | 1 |
| Schouten, MA | 1 |
| Girbes, AR | 1 |
| Conil, JM | 2 |
| Georges, B | 2 |
| de Lussy, A | 1 |
| Khachman, D | 2 |
| Seguin, T | 1 |
| Ruiz, S | 1 |
| Cougot, P | 1 |
| Fourcade, O | 1 |
| Houin, G | 2 |
| Saivin, S | 2 |
| Utrup, TR | 1 |
| Mueller, EW | 1 |
| Healy, DP | 1 |
| Callcut, RA | 1 |
| Peterson, JD | 1 |
| Hurford, WE | 1 |
| Toutain, PL | 1 |
| Laffont, CM | 1 |
| Kontou, P | 1 |
| Chatzika, K | 1 |
| Pitsiou, G | 1 |
| Stanopoulos, I | 1 |
| Argyropoulou-Pataka, P | 1 |
| Kioumis, I | 1 |
| Spooner, AM | 1 |
| Deegan, C | 1 |
| D'Arcy, DM | 1 |
| Gowing, CM | 1 |
| Donnelly, MB | 1 |
| Corrigan, OI | 1 |
| Sideri, G | 1 |
| Kafetzis, DA | 1 |
| Vouloumanou, EK | 1 |
| Papadatos, JH | 1 |
| Papadimitriou, M | 1 |
| Falagas, ME | 1 |
| Roberts, DM | 1 |
| Roberts, MS | 1 |
| Liu, X | 1 |
| Nair, P | 1 |
| Cole, L | 1 |
| Bellomo, R | 1 |
| Szałek, E | 1 |
| Tomczak, H | 1 |
| Kamińska, A | 1 |
| Grabowski, T | 1 |
| Smuszkiewicz, P | 1 |
| Matysiak, K | 1 |
| Wolc, A | 1 |
| Kaczmarek, Z | 1 |
| Grześkowiak, E | 1 |
| Bellmann, R | 1 |
| Egger, P | 1 |
| Gritsch, W | 1 |
| Bellmann-Weiler, R | 1 |
| Joannidis, M | 1 |
| Dunzendorfer, S | 1 |
| Wiedermann, ChJ | 1 |
| Kuberski, T | 1 |
| Robinson, L | 1 |
| Schurgin, A | 1 |
| Pea, F | 1 |
| Poz, D | 1 |
| Viale, P | 1 |
| Pavan, F | 1 |
| Furlanut, M | 1 |
| Forrest, A | 1 |
| Nix, DE | 1 |
| Ballow, CH | 1 |
| Goss, TF | 1 |
| Birmingham, MC | 1 |
| Schentag, JJ | 1 |
| Dutta, P | 1 |
| Rasaily, R | 1 |
| Saha, MR | 1 |
| Mitra, U | 1 |
| Bhattacharya, SK | 1 |
| Bhattacharya, MK | 1 |
| Lahiri, M | 1 |
| Cohn, SM | 1 |
| Sawyer, MD | 1 |
| Burns, GA | 1 |
| Tolomeo, C | 1 |
| Milner, KA | 1 |
| de Marie, S | 1 |
| VandenBergh, MF | 1 |
| Buijk, SL | 1 |
| Bruining, HA | 1 |
| van Vliet, A | 1 |
| Kluytmans, JA | 1 |
| Mouton, JW | 1 |
| Mimoz, O | 1 |
| Binter, V | 1 |
| Jacolot, A | 1 |
| Edouard, A | 1 |
| Tod, M | 1 |
| Petitjean, O | 1 |
| Samii, K | 1 |
| Malone, RS | 1 |
| Fish, DN | 1 |
| Abraham, E | 1 |
| Teitelbaum, I | 1 |
| Debon, R | 1 |
| Breilh, D | 1 |
| Boselli, E | 1 |
| Saux, MC | 1 |
| Duflo, F | 1 |
| Chassard, D | 1 |
| Allaouchiche, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetics of Ciprofloxacin in Critically Ill Patients - a Screening Study to Assess the Feasibility of Renal Function Markers to Predict Ciprofloxacin Clearance (CAPOEIRA)[NCT03016845] | 40 participants (Actual) | Observational | 2017-01-01 | Completed | |||
| Point-of-care Monitoring of Antibiotic Concentration in Blood With UV-VIS Absorption Spectroscopy[NCT04282785] | 100 participants (Anticipated) | Observational | 2019-04-26 | Active, not recruiting | |||
| Antibiotic Plasma Concentrations During Continuous Renal Replacement Therapy With a High Adsorption Membrane (oXiris®)[NCT04033029] | 20 participants (Actual) | Observational | 2021-01-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 trials available for ciprofloxacin and Critical Illness
| Article | Year |
|---|---|
Right dose, right now: bedside, real-time, data-driven, and personalised antibiotic dosing in critically ill patients with sepsis or septic shock-a two-centre randomised clinical trial.
Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; COVID-19; Critical Illness; Humans; Pandemics; Sepsis; | 2022 |
Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial.
Topics: Anti-Bacterial Agents; beta-Lactams; Ciprofloxacin; Critical Illness; Humans; Intensive Care Units; | 2022 |
Invasive Candida infections and the harm from antibacterial drugs in critically ill patients: data from a randomized, controlled trial to determine the role of ciprofloxacin, piperacillin-tazobactam, meropenem, and cefuroxime.
Topics: Age Factors; Aged; Anti-Bacterial Agents; APACHE; Candidiasis, Invasive; Cefuroxime; Ciprofloxacin; | 2015 |
An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Creatinine; Critical Illness; Female; | 2011 |
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Analysis of Variance; Bacterial Infections; Ciprofloxaci | 1993 |
Bioavailability of ciprofloxacin after multiple enteral and intravenous doses in ICU patients with severe gram-negative intra-abdominal infections.
Topics: Adult; Aged; Anti-Infective Agents; Biological Availability; Ciprofloxacin; Creatinine; Critical Car | 1998 |
Pharmacokinetic parameters of ciprofloxacin (500 mg/5 mL) oral suspension in critically ill patients with severe bacterial pneumonia: a comparison of two dosages.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Biological Availability | 2002 |
26 other studies available for ciprofloxacin and Critical Illness
| Article | Year |
|---|---|
Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Carrier State; Critical Ill | 2007 |
Dynamics of the QTc interval over a 24-h dose interval after start of intravenous ciprofloxacin or low-dose erythromycin administration in ICU patients.
Topics: Administration, Intravenous; Adult; Aged; Anti-Bacterial Agents; Ciprofloxacin; Critical Illness; El | 2021 |
[Ciprofloxacin: pharmacokinetics and a potential for therapeutic monitoring].
Topics: Anti-Bacterial Agents; Ciprofloxacin; Critical Illness; Drug Monitoring; Humans | 2021 |
Population pharmacokinetics of ciprofloxacin in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study).
Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; Critical Illness; Extracorporeal Membrane Oxygenation; | 2022 |
Higher Dosage of Ciprofloxacin Necessary in Critically Ill Patients: A New Dosing Algorithm Based on Renal Function and Pathogen Susceptibility.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Anti-Bacterial Agents; Bacteria; Bacterial Infections; C | 2020 |
Evaluation of Meropenem-Ciprofloxacin Combination Dosage Regimens for the Pharmacokinetics of Critically Ill Patients With Augmented Renal Clearance.
Topics: Anti-Bacterial Agents; Bacteriological Techniques; Ciprofloxacin; Creatinine; Critical Illness; Dose | 2021 |
Ciprofloxacin in critically ill subjects: considering hepatic function, age and sex to choose the optimal dose.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Creatinine; Criti | 2019 |
Treatment Outcomes of Stenotrophomonas maltophilia Bacteremia in Critically Ill Children: A Multicenter Experience.
Topics: Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Comorbidity; Critical Illness; Drug C | 2019 |
Ciprofloxacin pharmacokinetics in critically ill patients receiving concomitant continuous venovenous hemodialysis.
Topics: Aged; Anti-Bacterial Agents; Area Under Curve; Bacterial Infections; Ciprofloxacin; Critical Illness | 2015 |
Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models.
Topics: Animals; Anti-Infective Agents; Carbapenems; Caspofungin; Ceftriaxone; Ciprofloxacin; Critical Illne | 2015 |
Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aged; Anti-Bacterial Agents; Ciprofloxacin; Criti | 2016 |
Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Area Under Curve; Ciprofloxacin; | 2008 |
Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches.
Topics: Aged; Algorithms; Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Critical Illness; Female; Half-Lif | 2008 |
High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration.
Topics: Anti-Infective Agents; Ciprofloxacin; Critical Illness; Enterobacter aerogenes; Enterobacteriaceae I | 2010 |
Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations.
Topics: Acinetobacter baumannii; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciproflo | 2011 |
Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease.
Topics: Anti-Infective Agents; Bronchi; Chromatography, High Pressure Liquid; Ciprofloxacin; Critical Illnes | 2011 |
Ciprofloxacin in critically ill children.
Topics: Anti-Bacterial Agents; Bacteremia; Bacterial Infections; Child, Preschool; Ciprofloxacin; Critical C | 2011 |
Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.
Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; Ciprofloxacin; Critical Illness; Female; Hemofiltr | 2012 |
Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.
Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; Ciprofloxacin; Critical Illness; Female; Hemofiltr | 2012 |
Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.
Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; Ciprofloxacin; Critical Illness; Female; Hemofiltr | 2012 |
Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.
Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; Ciprofloxacin; Critical Illness; Female; Hemofiltr | 2012 |
Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg.
Topics: Adult; Aged; Anti-Infective Agents; Area Under Curve; Ciprofloxacin; Critical Illness; Female; Human | 2012 |
Pharmacokinetics of ciprofloxacin in patients with acute renal failure undergoing continuous venovenous haemofiltration: influence of concomitant liver cirrhosis.
Topics: Acute Kidney Injury; Anti-Infective Agents; Area Under Curve; Chromatography, High Pressure Liquid; | 2002 |
A case of plague successfully treated with ciprofloxacin and sympathetic blockade for treatment of gangrene.
Topics: Anti-Infective Agents; Ciprofloxacin; Critical Illness; Gangrene; Humans; Male; Middle Aged; Sepsis; | 2003 |
Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective.
Topics: Analysis of Variance; Anti-Bacterial Agents; Area Under Curve; Bacterial Infections; Chromatography, | 2006 |
Ciprofloxacin for treatment of severe typhoid fever in children.
Topics: Body Temperature; Carrier State; Child; Child, Preschool; Ciprofloxacin; Critical Illness; Humans; I | 1993 |
Enteric absorption of ciprofloxacin during tube feeding in the critically ill.
Topics: Adult; Aged; Anti-Infective Agents; APACHE; Ciprofloxacin; Critical Illness; Enteral Nutrition; Fema | 1996 |
Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients.
Topics: Adult; Aged; Anti-Infective Agents; Biological Availability; Chromatography, High Pressure Liquid; C | 1998 |
Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients.
Topics: Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Critical Illness; Female; Hemofiltration; Humans; | 2001 |